Seeking Alpha

FDA staff divided over Medicines Company's Cangrelor

  • It seems that FDA staff are divided over Medicines Company's (MDCO) Cangrelor drug for preventing blood clots.
  • As noted, one review has recommended that the drug should not be approved due to trial flaws.
  • However, ISI Group analyst Umer Raffat has pointed out that buried deep in an FDA briefing document, another review has recommended approval of Cangrelor (see page 11 of the document).
  • Shares were down 13% earlier but have recovered somewhat and are -5.8%.
  • Given the sensitive nature of these reviews for the market, surely the FDA should have given equal billing to a summary of both opinions at the beginning of the briefing document.
  • The FDA's recommendations come ahead of a meeting of an advisory committee that is due to take place on Wednesday.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: